Trial Profile
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Rose bengal sodium (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Provectus Biopharmaceuticals
- 19 Nov 2023 Planned End Date changed from 1 Nov 2024 to 1 Apr 2025.
- 19 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2023 According to a Provectus Biopharmaceuticals media release, company provided updated data from this study